WO2006110466A3 - CANCER-RELATED GENES (PTPϵ) - Google Patents

CANCER-RELATED GENES (PTPϵ) Download PDF

Info

Publication number
WO2006110466A3
WO2006110466A3 PCT/US2006/012863 US2006012863W WO2006110466A3 WO 2006110466 A3 WO2006110466 A3 WO 2006110466A3 US 2006012863 W US2006012863 W US 2006012863W WO 2006110466 A3 WO2006110466 A3 WO 2006110466A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
epsiv
ptp
related genes
gene
Prior art date
Application number
PCT/US2006/012863
Other languages
French (fr)
Other versions
WO2006110466A2 (en
Inventor
Abdallah Fanidi
Robert Booher
Albert Lai
Christin Tse
Original Assignee
Novartis Vaccines & Diagnostic
Sagres Discovery Inc
Abdallah Fanidi
Robert Booher
Albert Lai
Christin Tse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Sagres Discovery Inc, Abdallah Fanidi, Robert Booher, Albert Lai, Christin Tse filed Critical Novartis Vaccines & Diagnostic
Priority to EP06749428A priority Critical patent/EP1874959A2/en
Priority to US11/910,834 priority patent/US20090317391A1/en
Priority to JP2008505525A priority patent/JP2008535491A/en
Publication of WO2006110466A2 publication Critical patent/WO2006110466A2/en
Publication of WO2006110466A3 publication Critical patent/WO2006110466A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the tm-PTPϵ gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the tm-PTPϵ gene.
PCT/US2006/012863 2005-04-07 2006-04-07 CANCER-RELATED GENES (PTPϵ) WO2006110466A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06749428A EP1874959A2 (en) 2005-04-07 2006-04-07 CANCER-RELATED GENES (PTPepsilon)
US11/910,834 US20090317391A1 (en) 2005-04-07 2006-04-07 Cancer Related Genes (PTPE)
JP2008505525A JP2008535491A (en) 2005-04-07 2006-04-07 Cancer-related genes (PTPε)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66985605P 2005-04-07 2005-04-07
US60/669,856 2005-04-07
US78492506P 2006-03-22 2006-03-22
US60/784,925 2006-03-22

Publications (2)

Publication Number Publication Date
WO2006110466A2 WO2006110466A2 (en) 2006-10-19
WO2006110466A3 true WO2006110466A3 (en) 2007-03-08

Family

ID=37022876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/012863 WO2006110466A2 (en) 2005-04-07 2006-04-07 CANCER-RELATED GENES (PTPϵ)

Country Status (4)

Country Link
US (1) US20090317391A1 (en)
EP (1) EP1874959A2 (en)
JP (1) JP2008535491A (en)
WO (1) WO2006110466A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE477486T1 (en) * 2006-01-04 2010-08-15 Novartis Ag ANTIBODIES DEPENDENT CELLULAR CYTOTOXICITY TEST
CA2710471C (en) 2007-12-26 2018-06-05 Biotest Ag Immunoconjugates targeting cd138 and uses thereof
KR101626416B1 (en) * 2007-12-26 2016-06-01 바이오테스트 아게 Agents targeting cd138 and uses thereof
CN101945892B (en) * 2007-12-26 2017-11-24 生物测试股份公司 For the method and reagent of the targeting for improving the tumour cell to expressing CD138
WO2010023877A1 (en) * 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Prmt1 for target genes of cancer therapy and diagnosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054387A1 (en) * 2001-06-26 2003-03-20 Chen Jeremy J.W. Metastasis-associated genes
US20030225026A1 (en) * 2002-05-13 2003-12-04 Ari Elson Methods, compositions and articles of manufacture useful for treating mammary tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054387A1 (en) * 2001-06-26 2003-03-20 Chen Jeremy J.W. Metastasis-associated genes
US20030225026A1 (en) * 2002-05-13 2003-12-04 Ari Elson Methods, compositions and articles of manufacture useful for treating mammary tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELSON A ET AL: "Protein tyrosine phosphatase epsilon cytoplasmic isoform (Fragment)", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 44, 3 November 1995 (1995-11-03), pages 26116 - 26122, XP002310973 *
TOLEDANO-KATCHALSKI HILA ET AL: "Dimerization in vivo and inhibition of the nonreceptor form of protein tyrosine phosphatase epsilon.", August 2003, MOLECULAR AND CELLULAR BIOLOGY, VOL. 23, NR. 15, PAGE(S) 5460-5471, ISSN: 0270-7306, XP002401010 *

Also Published As

Publication number Publication date
EP1874959A2 (en) 2008-01-09
JP2008535491A (en) 2008-09-04
WO2006110466A2 (en) 2006-10-19
US20090317391A1 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
WO2006110581A3 (en) Cancer-related genes
WO2006110599A3 (en) Cacna1e in cancer diagnosis, detection and treatment
WO2006110594A3 (en) Sema4d in cancer diagnosis, detection and treatment
WO2006110587A3 (en) Ddr2 in cancer diagnosis, detection and treatment
WO2008039769A3 (en) Methods and devices for analyzing small rna molecules
TWI317811B (en)
WO2006074360A3 (en) Apolipoprotein a-ii isoform as a biomarker for prostate cancer
WO2006116362A3 (en) Structured substrates for optical surface profiling
WO2008008923A3 (en) Compositions and methods for targeting cancer-specific transcription complexes
WO2007095644A3 (en) Reagents and methods for cancer prognosis and pathological staging
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
HK1109804A1 (en) Proteolipid membrane and lipid membrane biosensor
WO2005039382A3 (en) Prediction of likelihood of cancer recurrence
ATE450547T1 (en) EML4-ALK FUSION GENE
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
WO2006089125A3 (en) Methods of detecting ovarian cancer
WO2007035766A3 (en) Biomarker for prostate cancer
WO2006037462A3 (en) Cancer markers
WO2006110466A3 (en) CANCER-RELATED GENES (PTPϵ)
WO2012120374A3 (en) Methods and biomarkers for detection of gastrointestinal cancers
WO2006116016A3 (en) Molecular determinants of egfr kinase inhibitor response in glioblastoma
WO2005034732A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
ATE514090T1 (en) USE OF THE PROTEIN SATB2 AS A MARKER TO DIFFERENTIATE COLORECTAL CARCINOMA FROM OTHER CANCER DISEASES
WO2007112054A3 (en) Facilitation of translocation of molecules through the gastrointestinal tract
EP1833844A4 (en) Signal peptides, nucleic acid molecules and methods of treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008505525

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2006749428

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11910834

Country of ref document: US